NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
Clinical Trials
11 trialsNCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT05218408 2023-02-16
CYNK001GBM02
Celularity Incorporated
Phase 1/2 Withdrawn
NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT02876003 2017-02-24
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
GenSpera, Inc.
Phase 2 Withdrawn
NCT01225510 2015-03-11
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Pfizer
Phase 2 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00083447 2009-01-07
Study of Therapy With TransMIDâ„¢ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
Xenova Biomedix
Phase 3 Withdrawn